Menu Search
Equities

Eloxx Pharmaceuticals Inc

3970:BER

Eloxx Pharmaceuticals Inc

Actions
  • Price (EUR)6.40
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+35.02%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2023 11:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-20.48m
  • Incorporated1999
  • Employees18.00
  • Location
    Eloxx Pharmaceuticals Inc480 ARSENAL WAY, SUITE 130WATERTOWN 02472United StatesUSA
  • Phone+1 (781) 577-5300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.eloxxpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.